title: Evaluation of right atrial and biatrial temporary pacing for the prevention of atrial fibrillation after coronary artery bypass surgery.
abstract: OBJECTIVE
  The purpose of this study was to determine if atrial pacing is effective in reducing postoperative atrial fibrillation (AF).
  
  
  BACKGROUND
  Atrial fibrillation after coronary artery bypass grafting (CABG) is a common problem for which medical management has been disappointing. Atrial-based pacing has become an attractive nonpharmacologic therapy for the prevention of AF.
  
  
  METHODS
  Sixty-one post-CABG patients (mean age = 65 years) were randomized to one of three groups: no atrial pacing (NAP), right atrial pacing (RAP) or biatrial pacing (BAP). Each patient had one set of atrial wires attached to both the right and left atria, respectively, at the conclusion of surgery. Patients in the RAP and BAP groups were continuously paced at a rate of 100 pulses per minute for 96 h or until the onset of sustained AF (>10 min). All patients were monitored with Holter monitors or full disclosure telemetry to identify the onset of AF. The primary end point of the study was the first onset of sustained AF.
  
  
  RESULTS
  There was no significant difference in the proportion of patients developing AF in the three groups (NAP = 33%; RAP = 29%; BAP = 37%; p > 0.7). However, for the subset of patients on beta-adrenergic blocking agents after CABG, there was a trend toward less AF in the paced groups. There were no serious complications related to pacing, although in three patients the pacemaker appeared to induce AF by pacing during atrial repolarization.
  
  
  CONCLUSIONS
  Continuous right or biatrial pacing in the postoperative setting is safe and well tolerated. We did not find that post-CABG pacing prevented AF in this pilot study; however, the role of combined pacing and beta-blockade merits further study.
authors.affiliation: Department of Medicine, University of Massachusetts Medical Center, Worcester 01655, USA.
authors.forename: E P
authors.initials: EP
authors.lastname: Gerstenfeld
authors.forename: M R
authors.initials: MR
authors.lastname: Hill
authors.forename: S N
authors.initials: SN
authors.lastname: French
authors.forename: R
authors.initials: R
authors.lastname: Mehra
authors.forename: K
authors.initials: K
authors.lastname: Rofino
authors.forename: T J
authors.initials: TJ
authors.lastname: Vander Salm
authors.forename: R S
authors.initials: RS
authors.lastname: Mittleman
mesh_terms: D000293:Adolescent; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000368:Aged; D001281:Atrial Fibrillation / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D002304:Cardiac Pacing, Artificial / Q000379:methods*; D001026:Coronary Artery Bypass / Q000009:adverse effects*; D015716:Electrocardiography, Ambulatory; D005260:Female; D005500:Follow-Up Studies; D006325:Heart Atria; D006801:Humans; D008297:Male; D010865:Pilot Projects; D011379:Prognosis; D012189:Retrospective Studies; D012449:Safety
chemical_list: D000319:Adrenergic beta-Antagonists